CT Scan for Visceral Fat: Results Explained

A CT scan for visceral fat is one of the most accurate methods available for measuring the deep abdominal fat that surrounds your organs and drives cardiometabolic risk. Unlike BMI or waist circumference, CT imaging can directly distinguish visceral adipose tissue from subcutaneous fat, providing a precise measurement that standard clinical tools cannot match. This article explains how CT scanning quantifies visceral fat, what your results mean in practice, which thresholds are associated with increased health risk, and what steps you can take, including lifestyle changes and clinically supervised treatments, to reduce visceral fat if your levels are elevated.

What is visceral fat and why does it matter for your health?

Visceral fat is metabolically active fat stored deep in the abdominal cavity that releases inflammatory substances into the portal circulation, significantly raising the risk of type 2 diabetes, cardiovascular disease and fatty liver disease, even in people with a normal BMI.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it carries significantly greater health risks than subcutaneous fat stored just beneath the skin. Unlike the fat you can pinch at the waist, visceral fat is not visible from the outside, which means a person with a seemingly normal body weight or waist circumference can still carry a clinically significant amount of it.

The reason visceral fat is considered particularly harmful is its proximity to the portal circulation. Fat cells in this region release fatty acids, inflammatory cytokines and hormones directly into the bloodstream supplying the liver, contributing to insulin resistance, raised triglycerides, elevated blood pressure and low-grade systemic inflammation. These changes collectively increase the risk of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called non-alcoholic fatty liver disease) and certain cancers.

NICE guidance on obesity and cardiometabolic risk acknowledges that waist circumference and body mass index (BMI) are imperfect proxies for metabolic risk, partly because they cannot distinguish visceral from subcutaneous fat. NICE also recommends considering waist-to-height ratio (a threshold of 0.5 is widely used) alongside BMI as a practical measure of central adiposity. Two people with identical BMI values can have very different visceral fat burdens and therefore very different risk profiles. This is particularly relevant in people of South Asian, East Asian and Black African heritage, in whom cardiometabolic risk tends to occur at lower BMI thresholds, as recognised in NICE guidance.

Understanding your visceral fat level, rather than relying on weight or BMI alone, can add useful risk information to your overall health picture and help guide decisions about lifestyle change or clinical intervention.

How does a CT scan measure visceral fat?

CT scanning produces cross-sectional abdominal images analysed by specialist software to calculate visceral adipose tissue area separately from subcutaneous fat, most commonly measured at the L4 to L5 vertebral level and expressed in cm².

A CT (computed tomography) scan and MRI are both considered highly accurate reference methods for quantifying visceral fat in clinical and research settings, because they can directly distinguish fat tissue from other abdominal structures based on differences in tissue density. CT uses X-ray beams from multiple angles to produce detailed cross-sectional images of the abdomen, and specialist software then analyses the resulting images to calculate the area or volume of visceral adipose tissue (VAT) separately from subcutaneous adipose tissue (SAT). MRI achieves comparable accuracy without using ionising radiation, though it is more expensive and less widely available.

In practice, visceral fat is most commonly measured at a single cross-sectional slice taken at the level of the fourth and fifth lumbar vertebrae (L4 to L5), a landmark validated in research as representative of total abdominal visceral fat. The result is typically expressed as a visceral adipose tissue area in square centimetres (cm²). Some protocols use volumetric measurements across multiple slices for greater precision, particularly in research contexts.

Because CT scanning involves ionising radiation, important safety points apply. CT should not be used in pregnancy unless clinically essential, and exposure should always be justified against the clinical benefit. CT is not routinely used in the NHS solely to measure fat distribution. In clinical practice, a CT scan ordered for another indication may incidentally provide visceral fat data if the images are analysed accordingly. Dedicated visceral fat CT scans are more commonly available through private health assessment services. Routine repeat CT scanning purely to monitor visceral fat over time is not recommended; waist circumference, metabolic blood tests and clinical review are more appropriate for ongoing monitoring.

Alternative imaging methods include MRI, which carries no radiation and is highly accurate, and dual-energy X-ray absorptiometry (DEXA), which estimates body composition including visceral fat but uses a low dose of ionising radiation and offers somewhat lower precision than CT or MRI. Ultrasound can estimate visceral fat depth but is operator-dependent and less standardised than cross-sectional imaging.

What do your CT scan results actually mean?

A VAT area of around 100 cm² at L4 to L5 is commonly associated with increased cardiometabolic risk, but results must be interpreted by a clinician alongside blood pressure, lipid profile, blood glucose and individual risk factors.

A CT scan result for visceral fat is typically reported as a visceral adipose tissue (VAT) area measured in cm². Research literature has used various thresholds to indicate increased cardiometabolic risk, with values in the region of 100 cm² at the L4 to L5 level commonly cited, and higher values (such as 160 cm² or above) used in some studies to define high-risk visceral obesity, particularly in men. However, these figures are derived from research populations and no single universally agreed clinical cut-off has been adopted across all UK guidelines; thresholds also vary by sex and ethnic background. Your result should always be interpreted by a clinician in the context of your full health picture, including blood pressure, lipid profile, blood glucose, family history and lifestyle factors.

Generally speaking, a higher VAT area is associated with a greater likelihood of metabolic abnormalities. Sex differences are clinically relevant: women tend to accumulate more subcutaneous fat relative to visceral fat before the menopause, but this pattern often shifts after menopause, increasing cardiometabolic risk.

If your scan results suggest elevated visceral fat, your GP or specialist may recommend further investigations, which could include:

• HbA1c as the first-line test to assess for insulin resistance or type 2 diabetes (fasting blood glucose may be used where HbA1c is not appropriate)

• Fasting lipid profile to check for dyslipidaemia

• Non-invasive liver assessment if fatty liver disease is suspected; UK pathways generally recommend a FIB-4 score as an initial step rather than ultrasound for case-finding, in line with current British Society of Gastroenterology guidance on MASLD^[10]

• Blood pressure monitoring

Follow-up investigations and any referrals will depend on your overall clinical findings and local Integrated Care Board (ICB) pathways. A result showing high visceral fat is not a diagnosis in itself but a risk marker that warrants a structured clinical conversation. If you receive such a result privately, sharing it with your GP ensures it is considered alongside your broader NHS health record.

Can you reduce visceral fat after a CT scan diagnosis?

Visceral fat responds well to sustained lifestyle changes, including aerobic exercise and reduced calorie intake, with even 5 to 10 per cent body weight loss producing meaningful reductions; pharmacological treatments such as GLP-1 receptor agonists may be considered under medical supervision.

Visceral fat responds more readily to lifestyle intervention than subcutaneous fat, and meaningful reductions are achievable through a sustained combination of dietary change, increased physical activity and, where clinically appropriate, pharmacological support. Research suggests that even a modest reduction in overall body weight of 5 to 10 per cent can produce substantial reductions in visceral adipose tissue, with accompanying improvements in insulin sensitivity, blood pressure and lipid levels.^[19]

From a dietary perspective, reducing overall calorie intake, limiting ultra-processed foods and refined carbohydrates, and following a Mediterranean-style or lower-carbohydrate dietary pattern have all been associated with reductions in visceral fat in clinical studies. Aerobic exercise, such as brisk walking, cycling or swimming, is particularly effective at reducing VAT.^[16][17] The UK Chief Medical Officers' physical activity guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults, and NICE guidance on physical activity supports this target.^[11][12] Resistance training provides additional metabolic benefit and helps preserve lean muscle mass during weight loss.

For people who meet the criteria set out in the relevant NICE Technology Appraisals, pharmacological treatments may be considered alongside lifestyle measures. Access on the NHS depends on specific NICE Technology Appraisal recommendations, local ICB commissioning decisions and, in most cases, referral to a specialist weight-management service. Licensed options that may be considered include orlistat; GLP-1 receptor agonists such as semaglutide (Wegovy, MHRA-authorised at maintenance doses of 2.4 mg once weekly and, for eligible patients, 7.2 mg once weekly, which are separate licensed dosing regimens) and liraglutide (Saxenda); the dual GIP and GLP-1 receptor agonist tirzepatide (Mounjaro), MHRA-authorised for both type 2 diabetes and chronic weight management; and orforglipron (Foundayo), which also holds a UK marketing authorisation for weight management.^[3][4] All weight-management medicines should be used under medical supervision. They are not suitable during pregnancy or breastfeeding, and your prescriber will review contraindications and suitability before prescribing. If you experience suspected side effects from any medicine, you can report them via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support. Mounjaro is one option a prescriber may consider following a consultation with Bolt Pharmacy, and is only prescribed where clinically appropriate.

Progress is best monitored through waist circumference, waist-to-height ratio, metabolic blood tests (such as HbA1c and lipid profile) and clinical review. Routine repeat CT scanning to track visceral fat is not recommended due to cumulative radiation exposure; where imaging is clinically necessary, non-ionising methods such as MRI should be considered. If you are concerned about your visceral fat levels, speak to your GP in the first instance to discuss the most appropriate management plan for your individual circumstances.

Frequently Asked Questions